Advances in Gastroenterology

Flexible sigmoidoscopy is one of numerous screening modalities advocated through America Preventive Services Task Force for colorectal cancer (CRC) screening. However, sigmoidoscopy is much less effective in detecting lesions at the proper facet of the colon than the left facet, and right-sided lesions are greater not unusual in older ladies. A take a look at that pooled outcomes from 3 randomized trials evaluating screening with the aid of sigmoidoscopy without a screening determined that the occurrence of CRC at 10 to 12 years was reduced in men however in ladies, best in those younger than 60 years. Current screening pointers do no longer suggest gender-primarily based alternatives for screening options. Gallbladder and Biliary Disease.

• Abdominal Imaging
• Ablation Therapies
• Hepatic Pathology
• Hepatic Lesions
• HELLP Syndrome

Market Statistics:

According to our new research study titled "Gastrointestinal Drugs Market to 2027 – Global Analysis and Forecast – by Drug Class, Route of Administration, Application, and Distribution Channel," the Gastrointestinal Drugs Market Size was valued at US$ 49,043.38 million in 2019 and is expected to reach US$ 71,300.28 million by 2027, growing at a CAGR of 4.9% between 2020 and 2027. The significant increase of COVID-19 infection propels market expansion.

Market for Gastrointestinal Drugs: Competitive Landscape and Key Developments:

Among the major players in the gastrointestinal medications market are Sanofi, GlaxoSmithKline plc, Bausch Health, AstraZeneca,  Johnson and Johnson Services, Inc., AbbVie Inc., Takeda Pharmaceutical Company Limited, Bayer AG, Celltrion Healthcare Co., Ltd., and Lexicon Pharmaceuticals, Inc.